← Leaderboards
Georg Michael Lauer
Massachusetts General Hospital
$24,583,765
Attributed
$32,215,687
Total exposure
16
Grants
14
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.5M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,782,512 · 18
By mechanism
U19$24,122,729 · 10
R01$15,611,606 · 5
R37$2,189,677 · 1
U01$1,380,000 · 1
R21$478,500 · 1
Top collaborators
- Raymond T Chung7 shared
- Miriam Antoinette Bredella5 shared
- Kathleen Elizabeth Corey5 shared
- Karen K Miller5 shared
- Michael Jeffrey Vinikoor4 shared
- Mansun Law3 shared
- Lia Laura Lewis-Ximenez3 shared
- E. John Wherry2 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Raymond T Chung$38,306,004
- Madhusmita Misra$12,646,884
- Pouneh Khadejeh Fazeli$3,583,785
- Markella V. Zanni$10,033,281
- Karen K Miller$23,499,917
Others in their field
Top investigators on “Immune”
- Lawrence Corey · Fred Hutchinson Cancer Center$680,290,567
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$541,067,641
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$470,748,611
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$342,310,423
- Judith S. Currier · University Of California Los Angeles$334,425,492
Research focus
ImmuneT-LymphocyteResponseImmune ResponseViralInfectionT Cell ResponseVirusCellsHepatitis C VirusImmunityCohortChronicImmunotherapyPersonsPathway InteractionsHepatitis CCd8b1 GeneVirus DiseasesCd8-Positive T-LymphocytesDesignExhaustionVaccinesMediating
Grant awards (78)
Durable Alteration of the Human Immune system after Infection or Immunotherapy$2,328,551
U19 · FY2025 · AI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$957,683
R01 · FY2025 · AI · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2025 · DK
Project 2: Durable impact of HCV on innate and adaptive immunity$677,806
U19 · FY2025 · AI · contact PI
HBV-specific T cell immunity in HBV/HIV coinfection$588,450
R37 · FY2025 · AI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$160,224
R01 · FY2025 · AI · contact PI
HBV-specific T cell immunity in HBV/HIV coinfection$136,858
R37 · FY2025 · AI
Durable Alteration of the Human Immune system after Infection or Immunotherapy$2,446,152
U19 · FY2024 · AI
Integrated analysis of HBV-specific CD4 T cell and B cell responses to define their role in chronic hepatitis B and HBV functional cure.$1,168,511
R01 · FY2024 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2024 · AI · contact PI
HBV-specific T cell immunity in HBV/HIV coinfection$725,950
R37 · FY2024 · AI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$704,322
R01 · FY2024 · DK
Project 2: Durable impact of HCV on innate and adaptive immunity$638,169
U19 · FY2024 · AI · contact PI
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy$877,874
U19 · FY2023 · AI · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2023 · AI · contact PI
HBV-specific T cell immunity in HBV/HIV coinfection$738,419
R37 · FY2023 · AI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2023 · DK
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2022 · AI · contact PI
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy$768,384
U19 · FY2022 · AI · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2022 · DK
T cells in HCV/HIV co-infection$648,499
R01 · FY2022 · DA · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$834,534
R01 · FY2021 · AI · contact PI
Estrogen Administration for the Treatment of NASH in Postmenopausal Women$733,668
R01 · FY2021 · DK
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy$681,634
U19 · FY2021 · AI · contact PI
T cells in HCV/HIV co-infection$648,499
R01 · FY2021 · DA · contact PI
Immunologic correlates of functional cure of HBV with immune checkpoint blockade$847,913
R01 · FY2020 · AI · contact PI
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy$789,106
U19 · FY2020 · AI · contact PI
T cells in HCV/HIV co-infection$648,499
R01 · FY2020 · DA · contact PI
Immune Control and Evadion during Acute HCV Infection$276,000
U01 · FY2020 · AI · contact PI
Project 1: Perturbation of Pre-Existing Immunity to Chronic Viral Infection Through Immunotherapy$720,185
U19 · FY2019 · AI · contact PI
T cells in HCV/HIV co-infection$648,499
R01 · FY2019 · DA · contact PI
Immune Control and Evadion during Acute HCV Infection$276,000
U01 · FY2019 · AI · contact PI
T cells in HCV/HIV co-infection$648,499
R01 · FY2018 · DA · contact PI
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection$482,876
U19 · FY2018 · AI · contact PI
Immune Control and Evadion during Acute HCV Infection$276,000
U01 · FY2018 · AI · contact PI
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection$475,281
U19 · FY2017 · AI · contact PI
CD4+ T Cells in Acute Versus Chronic HCV Infection$435,000
R01 · FY2017 · AI · contact PI
Immune Control and Evadion during Acute HCV Infection$276,000
U01 · FY2017 · AI · contact PI
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection$466,414
U19 · FY2016 · AI · contact PI
CD4+ T Cells in Acute Versus Chronic HCV Infection$435,000
R01 · FY2016 · AI · contact PI
Immune Control and Evadion during Acute HCV Infection$276,000
U01 · FY2016 · AI · contact PI
T cell responses at the site of infection$217,500
R21 · FY2016 · AI · contact PI
CD4+ T Cells in Acute Versus Chronic HCV Infection$543,750
R01 · FY2015 · AI · contact PI
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection$482,876
U19 · FY2015 · AI · contact PI
T cell responses at the site of infection$261,000
R21 · FY2015 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$795,032
U19 · FY2014 · AI · contact PI
Mechanisms of Restoring T Cell Immunity after Cure of Chronic Viral Infection$509,812
U19 · FY2014 · AI · contact PI
CD4+ T Cells in Acute Versus Chronic HCV Infection$435,000
R01 · FY2014 · AI · contact PI
Determinants of T-Cell mediated control in acute HCV Infection$265,716
U19 · FY2014 · AI · contact PI
Administrative Core$54,078
U19 · FY2014 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$847,330
U19 · FY2013 · AI · contact PI
Funtional T-cell Failure in Chronic HCV Infection$434,138
U19 · FY2013 · AI · contact PI
CD4+ T Cells in Acute Versus Chronic HCV Infection$408,900
R01 · FY2013 · AI · contact PI
Determinants of T-Cell mediated control in acute HCV Infection$349,773
U19 · FY2013 · AI · contact PI
Administrative Core$50,828
U19 · FY2013 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$795,032
U19 · FY2012 · AI · contact PI
Funtional T-cell Failure in Chronic HCV Infection$461,842
U19 · FY2012 · AI · contact PI
Determinants of T-Cell mediated control in acute HCV Infection$265,064
U19 · FY2012 · AI · contact PI
Administrative Core$60,979
U19 · FY2012 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$811,256
U19 · FY2011 · AI · contact PI
Funtional T-cell Failure in Chronic HCV Infection$412,433
U19 · FY2011 · AI · contact PI
Determinants of T-Cell mediated control in acute HCV Infection$225,096
U19 · FY2011 · AI · contact PI
Administrative Core$96,396
U19 · FY2011 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$838,700
U19 · FY2010 · AI · contact PI
Funtional T-cell Failure in Chronic HCV Infection$427,941
U19 · FY2010 · AI · contact PI
Determinants of T-Cell mediated control in acute HCV Infection$231,220
U19 · FY2010 · AI · contact PI
Administrative Core$101,220
U19 · FY2010 · AI · contact PI
Immune Control and Evasion During Acute HCV Infection$950,277
U19 · FY2009 · AI · contact PI
Funtional T-cell Failure in Chronic HCV Infection$438,683
U19 · FY2009 · AI · contact PI
The Role of CD8+ T-cell Responses In Acute Hepatitis C Virus Infection$257,980
U19 · FY2009 · AI · contact PI
Immune Control and Immune Evasion during Acute Hepatitis C Virus Infection$917,312
U19 · FY2008 · AI · contact PI
The Role of CD8+ T-cell Responses In Acute Hepatitis C Virus Infection$252,359
U19 · FY2008 · AI · contact PI
Supplemental Funds to Acquire HCV Volunteers$12,261
U19 · FY2008 · AI · contact PI
Immune Control and Evasion during Acute HCV Infection$12,261
U19 · FY2008 · AI · contact PI
Immune Control and Immune Evasion during Acute Hepatitis C Virus Infection$824,922
U19 · FY2007 · AI · contact PI
The Role of CD8+ T-cell Responses In Acute Hepatitis C Virus Infection$201,314
U19 · FY2007 · AI · contact PI
The Role of CD8+ T-cell Responses In Acute HCV Infection$192,190
U19 · FY2006 · AI · contact PI
The Role of CD8+ T-cell Responses In Acute HCV Infection$193,976
U19 · FY2005 · AI